However, for the next quarter century, these reports largely escaped clinical attention until studies and reviews effectively validated enteropathy with nearly all NSAIDs, including aspirin [3,4,5,6,7] and selective cyclo-oxygenase-2 (COX-2) inhibitors, which were originally designed to prevent upper GI injury [7,8]. This evidence concerns the gene PTGS2 and Abnormal intestine morphology.